stockrowJazz Pharmaceuticals PLC
JAZZ Healthcare Biotechnology
Jazz Pharmaceuticals PLC’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, up 4.88% from fiscal 2024.
- Revenue
- +10.4%
- EPS
- −280.5%
- Free cash flow
- −60.4%
- Total debt
- +3.88%
Quarter to September 2026, against a year earlier
Follow JAZZ
Alert me
Jazz Pharmaceuticals PLC (JAZZ) Net income
Jazz Pharmaceuticals PLC's net income for fiscal 2025 was −$356.1M, compared with $560.1M in fiscal 2024. Over the twelve months to 30 September 2026 it was $206.0M. Over the past ten years it has ranged from −$356.1M (fiscal 2025) to $560.1M (fiscal 2024) — the current reading is the lowest in ten years. Jazz Pharmaceuticals PLC ranks 21st of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$356.1M | — |
| FY2024 | $560.1M | 35.02% |
| FY2023 | $414.8M | — |
| FY2022 | −$224.1M | — |
| FY2021 | −$329.7M | — |
| FY2020 | $238.6M | (54.41%) |
| FY2019 | $523.4M | 17.06% |
| FY2018 | $447.1M | (8.35%) |
| FY2017 | $487.8M | 22.94% |
| FY2016 | $396.8M | 20.42% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$483.4M | — |
| Jun 2026 | $192.8M | (34.22%) |
| Mar 2026 | $293.1M | 44.06% |
| Dec 2025 | $203.5M | (19.07%) |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| EXEL Exelixis, Inc. compare | $885.1M |
| ASND Ascendis Pharma A/S compare | $865.9M |
| HALO Halozyme Therapeutics, Inc. compare | $485.4M |
| JAZZ Jazz Pharmaceuticals PLC | $206.0M |
| TECH Bio-Techne Corp compare | $181.9M |
| BMRN BioMarin Pharmaceutical Inc. compare | −$19.1M |
| KYMR Kymera Therapeutics, Inc. compare | −$349.4M |
| BBIO BridgeBio Pharma, Inc. compare | −$577.6M |
| SMMT Summit Therapeutics PLC compare | −$856.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on JAZZ
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement